Download PDF
Thromb Haemost 2011; 105(06): 1124
DOI: 10.1160/TH11-02-0120
Letters to the Editor
Schattauer GmbH

Reasons for aspirin resistance

Andrzej Szczeklik
1   Jagiellonian University Medical College, Department of Medicine, Kraków, Poland
› Author Affiliations
Further Information

Publication History

Received: 22 February 2011

Accepted after minor revision: 09 March 2011

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Szczeklik A, Musial J, Undas A. et al. Aspirin resistance. J Thromb Haemost 2005; 3: 1655-1662.
    CrossrefPubMedGoogle Scholar
  • 2 Henry P, Vermillet A, Boval B. et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Lordkipanidze M. Why an aspirin a day no longer keeps the doctor away …. Thromb Haemost 2011; 105: 209-210.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Szczeklik A, Musial J, Undas A. et al. Inhibition of thrombin generation by aspirin is blunted in hyper-cholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 948-954.
    CrossrefPubMedGoogle Scholar
  • 5 Undas A, Brummel KE, Musial J. et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
    CrossrefPubMedGoogle Scholar
  • 6 Szczeklik A, Dropinski J, Radwan J. et al. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb Vasc Biol 1992; 12: 548-553.
    CrossrefPubMedGoogle Scholar
  • 7 Merlini PA, Bauer KA, Oltrona L. et al. Persistent activation of coagulation mechanism in unstable an-gina and myocardial infarction. Circulation 1994; 90: 61-68.
    CrossrefPubMedGoogle Scholar
  • 8 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-232.
    CrossrefPubMedGoogle Scholar
  • 10 Nurden AT. Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet. 1997; 350: 1189-1191.
    CrossrefPubMedGoogle Scholar
  • 11 Undas A, Sanak M, Musial J. et al. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982-983.
    CrossrefPubMedGoogle Scholar
  • 12 Szczeklik A, Undas A, Sanak M. et al. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 965-967.
    CrossrefPubMedGoogle Scholar